Finding a Brixadi provider in Maryland takes more than a quick internet search. The right provider isn’t just one who can legally prescribe the medication , it’s one who stocks it, administers it in-office, accepts your insurance, and wraps the injection in a treatment model that actually supports recovery. This guide gives you the questions to ask before you book a single appointment.
What Brixadi Actually Is (and Why It Differs From Other Medications)
According to a 2020 Cochrane Review of 31 randomized controlled trials covering more than 5,000 participants, buprenorphine-based treatment reduces illicit opioid use and retains patients in treatment at significantly higher rates than no medication at all. That baseline matters, because Brixadi builds on it in a specific way: it delivers buprenorphine as a subcutaneous extended-release injectable, not a daily film or tablet dissolved under the tongue.
The mechanism works like this. A healthcare provider injects a small depot under the skin, typically in the abdomen or upper arm. That depot releases buprenorphine steadily over either a week or a month, depending on which formulation is used. There is no daily dosing to remember, no film to keep dry before it dissolves, and no medication in your home that creates diversion risk. The FDA approved Brixadi in May 2023, with efficacy established through the CAM2038 phase 3 clinical trial program, which demonstrated that subcutaneous extended-release buprenorphine produced comparable or superior outcomes to daily sublingual buprenorphine across multiple retention and opioid-use endpoints.
What this means in practice: if you have tried Suboxone films and found that consistency was the obstacle , missed doses during stressful days, difficulty with the sublingual administration routine, or simply the burden of daily adherence , Brixadi removes that variable entirely. The medication works whether or not you remembered to take something this morning.
How Brixadi Differs From Sublocade
Both Brixadi and Sublocade are subcutaneous injectable buprenorphine formulations, but they are not interchangeable. Sublocade is a once-monthly injection only. Brixadi, drawing from the CAM2038 phase 3 trial data, offers both weekly and monthly dosing options. That distinction is clinically meaningful.
The weekly option exists precisely because some patients benefit from dose stabilization before transitioning to monthly injections. During early treatment, a provider may want to adjust dosing based on how you respond before locking into a 28-day cycle. The weekly schedule creates that flexibility without requiring a return to daily oral medication. If you are evaluating providers, ask specifically which schedule they offer and whether they use the weekly option as a transitional bridge or as an ongoing maintenance approach. Not every provider who administers injectable buprenorphine has operational experience with both schedules. For a deeper look at how the weekly injection schedule works in practice, that detail matters before you commit to a provider.
What the Evidence Says About Injectable vs. Oral Buprenorphine
A 2023 analysis published in JAMA Network Open examined retention in treatment across formulations of buprenorphine and found that extended-release injectable formulations outperformed daily oral buprenorphine on missed-dose adherence outcomes, particularly among patients managing high-stress living environments. The plain-English translation: you cannot forget a shot you already received.
For patients managing co-occurring mental health conditions, chaotic schedules, or unstable housing, the forgetting variable is not a minor inconvenience , it is a genuine treatment risk. Oral buprenorphine requires daily self-administration under specific conditions. An extended-release injection delivered in a clinical setting removes that dependency entirely. The medication is present in your system regardless of what your day looks like.
Why Maryland’s Treatment Landscape Shapes Your Options
Maryland has one of the most severe opioid overdose crises in the United States. According to the Maryland Department of Health, the state recorded 2,395 total drug- and alcohol-related intoxication deaths in 2023, with fentanyl present in the overwhelming majority of overdose fatalities. SAMHSA’s 2023 National Survey on Drug Use and Health placed Maryland among the top-tier states for opioid use disorder prevalence relative to population. That volume of need does not translate automatically into an abundance of well-equipped providers.
Not every OUD treatment provider in Maryland is certified, trained, or operationally set up to administer Brixadi. The distinction between being authorized to prescribe buprenorphine and being genuinely prepared to administer injectable formulations is significant. Knowing what questions to ask is the practical skill that separates a productive first appointment from a wasted one.
The Medicaid Coverage Picture in Maryland
Maryland Medicaid, administered through the HealthChoice managed care program, covers Brixadi as a covered benefit for eligible members with opioid use disorder. Coverage does not eliminate every barrier. Prior authorization requirements vary by managed care organization, and not every provider who accepts Medicaid has completed the administrative setup required to bill for in-office injectable buprenorphine administration.
Before your first call, have your Medicaid plan name and member ID ready. Ask the provider directly: do you accept Maryland Medicaid for Brixadi injections, and do you handle the prior authorization process in-house? Both answers matter. A provider who accepts Medicaid but requires you to navigate prior authorization on your own creates a meaningful access obstacle at exactly the wrong moment in treatment.
Commercial Insurance and No-Coverage Scenarios
Commercial insurance coverage for Brixadi varies by plan, and some insurers apply step therapy requirements, meaning they require documentation that a patient has attempted oral buprenorphine before approving coverage for an injectable formulation. If your plan includes this requirement, your provider will need to submit documentation of prior treatment history to support the authorization.
For patients without any insurance coverage, Braeburn, the manufacturer of Brixadi, operates a patient assistance program that provides access to the medication at reduced or no cost for qualifying individuals. Do not assume cost is an insurmountable barrier before asking. The provider’s front desk or care coordinator should be able to tell you whether they work with the Braeburn assistance program and what the application process looks like. Maryland also funds OUD treatment through the state Behavioral Health Administration, and some practices serving uninsured patients operate under block grant or state-funded program structures. Ask directly , the question takes thirty seconds and the answer can change your options entirely.
The First Question to Ask Any Provider: Do You Actually Stock and Administer Brixadi?
A 2023 HHS Office of the Assistant Secretary for Health report found that a substantial gap persists between the number of clinicians with buprenorphine prescribing authorization and those who are actively treating patients with any buprenorphine formulation at all. That gap narrows further when you isolate for injectable buprenorphine specifically. Stocking an injectable medication requires cold-chain storage infrastructure, staff trained in subcutaneous injection technique, and the administrative and billing framework to support in-office administration. A provider can be fully authorized to prescribe Brixadi and still have none of that infrastructure in place.
The simplest version of this: ask on the phone before you drive anywhere. “Do you stock and administer Brixadi in the office?” is a complete question that will tell you whether the appointment is worth scheduling. Providers who administer it regularly will answer without hesitation. Providers who don’t , or who are still setting up the capability , will tell you something less direct.
For a broader sense of where to access injectable buprenorphine in the state, understanding the provider landscape helps frame your search before you start calling.
What “In-Office Administration” Actually Means for Your Schedule
Brixadi is not a take-home medication. A healthcare professional must administer every injection in a clinical setting. During the weekly dosing phase, that means a visit to the provider’s office every seven days. For patients in Baltimore, College Park, Linthicum Heights, Nottingham, and Owings Mills, this is a realistic logistics question: how long does it take you to get there, and can you reliably make that trip once a week?
Before committing to a provider, map the commute. Account for public transit if you don’t drive, for work schedules if the clinic only has weekday hours, and for childcare if that affects appointment flexibility. A medication that requires consistent weekly visits only works if the office is consistently reachable. A provider two buses away with limited appointment windows is a retention risk before treatment even begins.
Question Two: What Does the Full Treatment Model Look Like?
A 2022 study published in Drug and Alcohol Dependence, drawing on data from the National Drug Abuse Treatment Clinical Trials Network, found that patients receiving medication for opioid use disorder alongside structured behavioral health support had significantly higher 12-month retention rates than patients receiving medication alone. The injection handles cravings and withdrawal; the rest of the treatment model handles the behavioral, psychological, and social dimensions of recovery that medication cannot reach.
Ask any prospective provider: is counseling integrated into this practice, referred out to another provider, or treated as optional? Each answer carries different practical implications. Integrated counseling means you see a therapist or counselor at the same location, often the same day as your injection. Referred counseling means you are responsible for making and keeping a separate appointment. Optional counseling means the practice does not consider it a required component of treatment at all , which, based on the evidence, is a limitation worth weighing. To understand what a full structured program looks like, the scope of services matters as much as the medication itself.
Evaluating the Intake and Induction Process
A legitimate intake process looks like this: a clinical assessment that includes your substance use history and medical background, a urine drug screen, an informed consent discussion covering how Brixadi works and what to expect from the dosing schedule, and a clinical conversation about which formulation schedule fits your situation. The American Society of Addiction Medicine (ASAM) criteria provide the clinical standard for OUD assessment, and any provider offering Brixadi should be applying those criteria during intake.
The red flag is pressure. A provider who skips the clinical assessment, pushes you toward a dosing commitment before reviewing your history, or moves you through intake in a way that feels more administrative than clinical is not following evidence-based standards. The intake appointment is where the clinical relationship is established. How a practice conducts it reflects how it will handle dose adjustments, missed appointments, and complications later.
Co-Occurring Mental Health Conditions: What to Ask
According to the 2023 SAMHSA National Survey on Drug Use and Health, approximately 48% of adults with a substance use disorder also meet criteria for at least one co-occurring mental health condition. Among people with opioid use disorder specifically, depression, anxiety, and post-traumatic stress disorder are the most commonly co-occurring diagnoses. That statistic has a direct implication for how you evaluate a provider.
Ask whether the practice has psychiatric support available on-site or a clearly defined referral pathway to psychiatric care. “We can refer you if needed” is meaningfully different from “we have a prescriber on staff.” If you are managing depression, anxiety, or trauma alongside opioid use disorder, the treatment model needs to address both , because undertreated mental health conditions are one of the most common reasons people leave OUD treatment before it has a chance to work. Ask this question explicitly before you enroll, not after your second missed therapy appointment.
Question Three: Who Is on Your Care Team?
A 2022 analysis in the Journal of Substance Abuse Treatment examined prescribing patterns across physician, nurse practitioner, and physician assistant providers following the expansion of buprenorphine prescribing authority. It found that outcomes , measured by retention and opioid-negative urine screens , did not differ significantly by credential type. What mattered more was experience volume and the availability of wraparound support services. The 2023 Mainstreaming Addiction Treatment Act eliminated the separate X-waiver requirement entirely, meaning a broader range of licensed providers can now prescribe buprenorphine. The credential matters less than the experience.
Ask how many patients the practice currently manages on Brixadi specifically, not just on buprenorphine broadly. Volume signals genuine familiarity with the medication’s specific clinical profile: how to handle dose adjustments, what to monitor between injections, and how to support patients through the transition from weekly to monthly dosing. A provider who has administered Brixadi to dozens of patients will answer questions about the medication with specificity. One who has administered it to a handful will not.
Peer Support and Case Management
Maryland’s Peer Recovery Specialist program trains individuals with lived recovery experience to provide support alongside clinical staff in treatment settings. A 2021 study published in Addiction Science and Clinical Practice, examining peer support integration in OUD treatment programs, found that peer specialist involvement was associated with a 23% reduction in treatment dropout over six months compared to programs without peer support. The mechanism is direct: a peer specialist bridges the gap between clinical appointments through shared experience, not clinical authority.
Ask whether the practice employs peer support staff or facilitates connection to community peer recovery programs. This is not a secondary consideration. For patients early in treatment, having access to someone who has navigated the same process , and who is available between injection appointments , changes the texture of recovery. A program that offers only clinical contact and nothing in between is missing a proven retention tool.
Question Four: How Does the Practice Handle Dose Adjustments and Missed Appointments?
A 2023 study in the American Journal of Psychiatry examining buprenorphine dose adequacy found that patients receiving doses calibrated to their individual response rather than standard protocols had measurably better outcomes on craving and opioid-use measures at six months. With injectable buprenorphine, the patient cannot self-adjust. That responsibility sits entirely with the provider, which makes the provider’s responsiveness between scheduled visits a clinical variable, not a convenience feature.
If your cravings spike noticeably in the days before your next scheduled injection, you need a provider who has a clear same-week callback protocol , a way to reach a clinician who can assess whether a dose or schedule adjustment is warranted. A practice where “call us and we’ll get back to you within two weeks” is the standard response to between-visit concerns is not equipped for the clinical reality of injectable buprenorphine treatment.
What Happens If You Miss an Injection Appointment
Missing a weekly Brixadi injection is not equivalent to missing a daily pill , the clinical implications differ , but it does matter, and how a practice handles it tells you a great deal about the program’s philosophy. SAMHSA and ASAM both emphasize non-punitive approaches to lapses and missed appointments in OUD treatment, recognizing that missed visits are often a symptom of the same instability that treatment is trying to address, not a reason to remove a patient from care.
Ask directly: what is your policy if I miss an injection appointment? A strong answer includes a defined makeup protocol, a clinical check-in to understand what happened, and a path back into the regular schedule without administrative penalty. A weak answer involves discharge after a single missed appointment without any clinical conversation. That policy is not consistent with evidence-based care guidelines, and it is a meaningful red flag.
Telehealth and In-Person Hybrid Options
Following the federal expansions of 2020, the DEA and HHS established expanded telehealth prescribing flexibilities for buprenorphine that remained in place through 2024 under a series of temporary rules. The injection itself must be administered in person , that is a firm clinical and regulatory requirement. But assessment appointments, follow-up consultations, counseling sessions, and medication check-ins can often be conducted via video, depending on your provider’s setup and your state’s current telehealth rules.
Ask whether the practice offers hybrid scheduling , telehealth for follow-up visits combined with in-person appointments for injections. For patients in suburban or more distant parts of Maryland, this arrangement can meaningfully reduce travel burden without reducing clinical contact. The injection keeps you connected to care; virtual visits maintain the relationship between those appointments.
Question Five: What Are the Real Costs, and What Assistance Exists?
SAMHSA has estimated the economic cost of untreated opioid use disorder at more than $78,000 per person per year when accounting for healthcare, criminal justice, and lost productivity costs. Brixadi has a cost. Untreated opioid use disorder has a much larger one. The relevant question is not whether the medication is expensive in isolation, but what your actual out-of-pocket exposure is given your coverage situation , and what assistance exists if cost is a barrier.
For Medicaid-covered patients, the out-of-pocket cost is typically minimal or zero when the provider is in-network and prior authorization is in place. For commercially insured patients, cost-sharing depends on the plan’s formulary placement and whether Brixadi requires a specialty tier copay. For uninsured patients, Braeburn’s patient assistance program is the first resource to ask about. Some Maryland practices serving uninsured patients also operate under state block grant funding through the Maryland Behavioral Health Administration, which can cover medication costs for qualifying individuals. If you are weighing whether to pursue injectable buprenorphine treatment because of cost concerns, ask the provider about every available assistance pathway before making a decision based on the list price alone.
Understanding Prior Authorization Requirements
Step therapy requirements , policies that require a patient to try and document failure of a first-line treatment before approving a second , are common in commercial insurance and some Medicaid managed care plans for injectable buprenorphine. In practice, this means some insurers require documentation that you have previously been treated with oral buprenorphine before they will approve coverage for Brixadi.
Ask the provider whether they handle prior authorization in-house and what their typical approval timeline looks like. Practices with experience in prior authorization for injectable buprenorphine typically have a designated staff member who manages this process and can give you a realistic timeline. Practices without that infrastructure may leave the burden on you , which, during the early days of seeking treatment, is a real barrier.
When to Ask About Sliding Scale or Grant-Funded Care
Maryland’s Behavioral Health Administration funds OUD treatment through a combination of federal block grants and state appropriations. Some practices participate in these programs and can serve patients at reduced or no cost, depending on income and eligibility. If you are uninsured or underinsured, ask every provider you contact whether they participate in any state-funded or grant-supported program. Not all practices advertise this capacity, but many have it.
A sliding scale fee structure means your payment is adjusted based on your income, not the market rate for the service. Ask for this explicitly. The worst outcome is assuming cost is a fixed barrier and not pursuing care when a funded pathway exists.
Red Flags to Watch for When Evaluating a Provider
A 2022 HHS Office of Inspector General report examining OUD treatment quality found that a subset of practices billing for medication-assisted treatment provided inadequate clinical assessment, no documented treatment plans, and minimal to no counseling alongside prescribing. These are not edge cases , they represent a pattern worth knowing how to recognize.
The red flags to watch for are concrete. No clinical intake assessment before the first injection is a problem. Unwillingness to discuss what happens if you miss an appointment is a problem. No written treatment plan that covers your goals, your dosing schedule, and the behavioral support component of care is a problem. A dismissive response when you ask about co-occurring depression or anxiety is a problem. Pressure to commit to a payment plan or enroll in services before you have received a clinical evaluation is a problem.
You have the right to ask questions at any point in the intake process. A provider operating according to evidence-based standards will welcome those questions, not deflect them. If your first appointment includes any of the patterns above, seeking a second opinion is not starting over , it is making a better decision with more information. For a practical guide on what to look for when evaluating a provider specifically, the details of that evaluation matter.
Comparing Providers Across Maryland’s Key Metro Areas
SAMHSA’s treatment locator data consistently shows that buprenorphine prescriber density is concentrated in urban and suburban areas, with meaningful gaps in rural parts of Maryland. Baltimore City and the surrounding metropolitan areas , including College Park, Linthicum Heights, Nottingham, and Owings Mills , have a more developed OUD treatment infrastructure than the state’s rural counties. That doesn’t mean every urban provider is well-equipped; it means the pool of options is larger, which gives you more room to be selective.
The Maryland Alcohol and Drug Abuse Administration (ADAA) maintains a provider directory that includes treatment programs by county and service type. SAMHSA’s treatment locator at findtreatment.gov allows you to filter by substance, medication type, and location. Use both, but treat the results as a starting list rather than a vetted recommendation. The locator tells you who is authorized to provide buprenorphine treatment , it does not tell you who stocks Brixadi, who accepts your specific Medicaid plan, or who has a high-volume injectable buprenorphine practice. Those answers come from calling.
For a more targeted look at how to navigate the search process across the state, understanding the geography of access is step one.
The Questions to Bring to Your First Appointment
The most productive first call or intake appointment is one where you arrive with specific questions and a clear sense of what a strong answer looks like versus a weak one. The following questions are drawn from every section of this guide, ordered by leverage , start with the ones that can eliminate a poor fit before you invest more time.
The first question is the one that filters fastest: do you stock and administer Brixadi in the office? A yes moves the conversation forward. A no or a non-answer ends it, and the call took three minutes.
The second question addresses the dosing schedule: do you offer weekly injections, monthly injections, or both? A strong answer explains how the practice decides which schedule fits a patient’s stage of treatment. A weak answer is uncertainty about which options are available.
Third, confirm insurance: do you accept my specific Medicaid plan (or commercial insurance) for Brixadi injections, and do you handle prior authorization in-house? The in-house question matters. Practices that handle authorization internally move faster and create fewer barriers at the moment you are trying to start treatment.
Fourth, ask about the treatment model: is counseling integrated into this practice, referred out, or optional? What happens to my care if I miss a counseling appointment?
Fifth, if you are managing a co-occurring mental health condition: do you have psychiatric support on-site, or is there a referral pathway? How quickly can I access that support after enrollment?
Sixth, ask about missed appointments: what is your policy if I miss a scheduled injection? What does the makeup process look like?
Seventh, ask about peer support: does the practice have peer recovery specialists on staff, or do you connect patients to community peer support programs?
Finally, if cost is a factor: do you participate in any state-funded programs, sliding scale arrangements, or the Braeburn patient assistance program for uninsured or underinsured patients?
Write down three of these questions before the call, not after. The ones that matter most are the ones specific to your situation: your insurance, your co-occurring conditions, and your logistical constraints around weekly appointments. The call goes better when you have the questions in front of you.
For a broader comparison of what distinguishes high-quality Brixadi programs across the state, these questions give you a framework to evaluate every option consistently.
What to Try This Week
Call one Maryland Brixadi provider today and ask the first question from this guide: do you stock and administer Brixadi in the office? That single question tells you more than any website listing. If the answer is yes, ask the second question about the dosing schedule, and then book the intake appointment. If the answer is no, the call took three minutes and you move to the next number on the list.
No extended research session is required before making that call. The SAMHSA locator at findtreatment.gov filtered for buprenorphine in your county gives you a starting list. The phone call is where the actual evaluation happens. Start there.